Baxter Expects Hurricane Helene Aftermath To Impact Near-Term Financial Outlook

Baxter International Inc. (NYSE:BAX) reported a third-quarter 2024 adjusted EPS of 80 cents, beating the management guidance of 77 cents to 79 cents and the Wall Street estimate of 78 cents.

This was driven by top-line strength in Medical Products & Therapies and Kidney Care, continued improvements in the integrated supply chain, and disciplined operating expense management.

Also Read: US Hospitals Face Critical IV Fluid Shortage After Baxter Facility Shuts Down Due To Hurricane Helene

The Deerfield, Illinois-based company reported sales of $3.85 billion, in line with consensus.

Baxter’s worldwide sales include continuing sales of $2.69 billion and discontinued operations (kidney care) sales of $1.15 billion.

Excluding Q3 2023 BioPharma Solutions (BPS) sales and including sales of Kidney Care in both periods, worldwide Baxter sales grew 4% on both a reported and ...

Full story available on Benzinga.com